The author of the seminal cancer biography The Emperor Of All Maladies and the co-founder of LinkedIn are looking to connect ...

With continued investment and growing buzz from the industry, the AI hype is expected to extend through 2025 and beyond.

Via AI methodologies, trial sponsors can simulate outcomes for different clinical development pathway scenarios to evaluate ...

AI models are able to design molecules that don’t even exist in nature. Some have proven effective as snake antivenom.

A new study from Oregon Health & Science University has uncovered how small molecules within bacteria interact with proteins, ...

While the presidential transition commanded headlines this week, equally significant shifts were occurring in AI technology. Just hours before Donald Trump’s inauguration, DeepSeek released its latest ...

Insilico Medcine( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced the first patient has been dosed in the global multicenter Phase I ...

Shares of Schrödinger soared by 15% mid-day Tuesday as the company, known for leveraging quantum mechanics in medicine and material design, embraces artificial intelligence (AI) to enhance its drug ...

The CEO of Google Mind has suggested clinical trials of the first drugs designed with the help of AI could begin this year.

Innophore will launch the CavitOmiX AI tool to screen for new drugs, predict side effects, and repurpose existing molecules.

Isomorphic was spun out of Google’s AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its ...

Healthcare technology company Innovaccer announced its acquisition of Humbi AI, an actuarial software, services and analytics ...